EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Mortality in Autoimmune Liver Disease in Sweden: A Population‐Based Cohort Study of 9,654 Patients

Imante Lasyte iD, Linnea Widman, Annika Bergquist iD, Hannes Hagström iD

Liver International · 2025

DOI: 10.1111/liv.70007 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Liver International, 2025. Verfasst von Imante Lasyte und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden. Hauptthemen laut MEDLINE: Hepatitis, Autoimmune, Cholangitis, Sclerosing, Liver Cirrhosis, Biliary. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Region Värmland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims Epidemiological data on mortality in autoimmune liver diseases (AILDs) are scarce. We examined all‐cause and cancer‐related mortality in individuals with AILD from Sweden.

Methods

We identified 9654 individuals with AILD (3342 with autoimmune hepatitis (AIH), 3751 with primary biliary cholangitis (PBC), and 2561 with primary sclerosing cholangitis (PSC)) using national Swedish registries between 2001 and 2020. These were matched with 80 685 comparators from the general population at a ratio of 1:10 on age, sex, year of diagnosis and municipality. Rates of outcomes were estimated using Cox regression models, adjusted for matching factors and cardiovascular disease, diabetes, inflammatory bowel disease, chronic obstructive pulmonary disease, and education.

Results

Individuals with AILD had higher mortality than comparators (adjusted hazard ratio (aHR) = 2.3, 95% CI = 2.2–2.4) and higher rates of cancer‐related death (aHR = 2.1, 95% CI = 1.9–2.3). The presence of liver cirrhosis in AILD was related to even higher mortality, with aHR 5.8 (95% CI = 5.1–6.6). Both males and females with AILD had increased mortality (males aHR = 2.6, 95% CI = 2.4–3.0, and females aHR = 2.2, 95% CI = 2.1–2.3). The mortality was higher in individuals aged 18–50 years (aHR = 4.6, 95% CI = 3.6–5.8), than in individuals above 50 years (aHR = 2.2, 95% CI = 2.1–2.3). Overall mortality rates and cancer‐related death were particularly high in individuals with PSC compared to their matched comparators, with aHR = 4.1 (95% CI = 3.2–5.2) and aHR = 6.4 (95% CI = 4.0–10.3), respectively.

Conclusions

Patients with AILDs have increased rates of overall and cancer‐related mortality compared to matched comparators, and relative risks are highest in cirrhosis, younger age and PSC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis, AutoimmuneCholangitis, SclerosingLiver Cirrhosis, BiliaryHumansSwedenMaleFemaleMiddle AgedAdultAgedRegistriesProportional Hazards ModelsYoung AdultAdolescentCause of DeathCohort StudiesNeoplasmsRisk FactorsLiver Neoplasms

Stichwörter der Autor:innen

autoimmune liver diseasecancer‐related mortalitydeathepidemiology

Autor:innen und Institutionen

  • Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden.
  • Division of Gastroenterology, Department of Medicine, Central Hospital, Karlstad, Sweden.
  • Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Imante Lasyte, Annika Bergquist, Hannes Hagström

Förderung

  • Region Värmland

Zitieren

APA

Lasyte, I., Widman, L., Bergquist, A., & Hagström, H. (2025). Mortality in Autoimmune Liver Disease in Sweden: A Population‐Based Cohort Study of 9,654 Patients. Liver International. https://doi.org/10.1111/liv.70007

Vancouver

Lasyte I, Widman L, Bergquist A, Hagström H. Mortality in Autoimmune Liver Disease in Sweden: A Population‐Based Cohort Study of 9,654 Patients. Liver International. 2025. doi:10.1111/liv.70007

BibTeX
@article{Lasyte2025,
  author = {Lasyte, Imante and Widman, Linnea and Bergquist, Annika and Hagström, Hannes},
  title = {Mortality in Autoimmune Liver Disease in Sweden: A Population‐Based Cohort Study of 9,654 Patients},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70007}
}
Kostenlos starten →